DALLAS, Jan. 20, 2020 /PRNewswire/ -- The Texas
Orthobiologic Institute today announced a new clinical
study evaluating three nonsurgical treatment protocols for
minimizing pain and dysfunction for patients with knee arthritis.
The study is called the HYP study and will evaluate
viscosupplementation and platelet-rich plasma (PRP)
treatments. The HYP study will be randomized and
double-blinded in order to provide a very high level of evidence.
Patients will be assigned to one of three treatment groups:
viscosupplementation, PRP, or a combination of
viscosupplementation and PRP. The study director is a
board-certified orthopedic surgeon, Don
Buford, MD, RMSK, who anticipates enrolling a total of 150
patients with knee arthritis into the HYP study. The study
does not involve surgery and the treatments are all injections that
will be done in the office. Both viscosupplementation and PRP
have been shown to be safe therapies for knee arthritis, however,
their combination has not been studied in a rigorous treatment
protocol to date.
The Texas Orthobiologic Institute was founded to evaluate
and use non-narcotic, nonsurgical treatments to help minimize
patient pain and dysfunction from orthopedic conditions like
arthritis. The Institute relies on evidence-based,
regulatory-compliant treatment protocols, and the HYP study
will be another example of the Institute's focus on improving
clinical evidence for orthobiologic treatments in
orthopedics.
There is no additional patient cost to be evaluated
for enrollment in the study. "Our belief is that patients
helping to contribute to medical research by participating in
studies should not have to pay," said Don Buford, MD. The
Texas Orthobiologic Institute expects to enroll
patients through 2020 and to follow patients in the study
for one year after treatment.
"Knee arthritis is a significant U.S. health concern that causes
pain and disability. The USA
spends millions of dollars a year on medications, injections, and
surgeries to minimize pain and disability from knee arthritis. Our
study is designed to show which is the best injection protocol
using viscosupplementation and platelet-rich plasma in a way that
has not been studied previously," said Don
Buford, MD, the Founder of the Texas
Orthobiologic Institute.
For additional information, the Study Coordinator can be reached
at 877-211-4471
Media Contact:
Don Buford, MD
Phone: 214-924-9242
Email: donbufordmd@gmail.com
Related Images
texas-orthobiologic-institute.png
Texas Orthobiologic Institute
View original content to download
multimedia:http://www.prnewswire.com/news-releases/study-on-new-treatments-for-knee-arthritis-pain-now-enrolling-new-patients-300989753.html
SOURCE The Texas Orthobiologic Institute